CLINICAL TRIALS PROFILE FOR INSULIN ASPART
✉ Email this page to a colleague
Biosimilar Clinical Trials for insulin aspart
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT05539872 ↗ | Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers | Recruiting | Amphastar Pharmaceuticals, Inc. | Phase 2/Phase 3 | 2022-08-22 | This study is a randomized, double-blinded, two-treatment, two-period, two-sequence crossover pivotal Biosimilar study. The purpose of this study is to establish pharmacokinetic (PK) and pharmacodynamics (PD) biosimilarity of proposed biosimilar I004 and the US-approved NovoLog. |
| NCT05802862 ↗ | A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China | Not yet recruiting | Sunshine Lake Pharma Co., Ltd. | Phase 3 | 2023-05-01 | The purpose of this study is to see if Insulin Degludec/Insulin Aspart (22011) compared to Insulin Degludec/Insulin Aspart (Ryzodeg) is similar in safety and effect in participants with type 2 diabetes (T2D). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for insulin aspart
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00046150 ↗ | 12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes. | Completed | Sanofi | Phase 3 | 2002-05-01 | The purpose of this study is to compare the safety of HMR 1964 and insulin aspart when used in external pumps with respect to catheter occlusions, GHb assessment, insulin doses, blood glucose parameters, hypoglycemic episodes, unexplained hyperglycemia, adverse events, laboratory data, and vital signs. |
| NCT00065130 ↗ | Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes | Completed | Novo Nordisk A/S | Phase 3 | 2000-04-01 | This trial is conducted in the United States of America (USA). The purpose of this study is to test whether NovoLog (insulin aspart) is a safe and at least as effective alternative to regular human insulin for the control of blood glucose after meals in women who develop diabetes during pregnancy. |
| NCT00071448 ↗ | Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population | Completed | Novo Nordisk A/S | Phase 3 | 2002-06-01 | This trial is conducted in the United States of America (USA). The aim of this trial is to to determine whether insulin aspart can be used effectively and safely in paediatric patients. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for insulin aspart
Condition Name
Clinical Trial Locations for insulin aspart
Trials by Country
Clinical Trial Progress for insulin aspart
Clinical Trial Phase
Clinical Trial Sponsors for insulin aspart
Sponsor Name
